CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study-Reference-Cited by-同舟云学术

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Published:2014-07 Issue:1 Volume:168 Page:16-22.e1
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Bergmeijer Thomas O.,Janssen Paul W.A.,Schipper Jurjan C.,Qaderdan Khalid,Ishak Maycel,Ruitenbeek Rianne S.,Asselbergs Folkert W.,van ‘t Hof Arnoud W.J.,Dewilde Willem J.M.,Spanó Fabrizio,Herrman Jean-Paul R.,Kelder Johannes C.,Postma Maarten J.,de Boer Anthonius,Deneer Vera H.M.,ten Berg Jurriën M.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

2. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC);Authors/Task Force Members;Eur Heart J,2012

3. Clopidogrel resistance: fact and fiction;van Werkum;Future Cardiol,2006

4. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation;Breet;JAMA,2010

5. Genetic determinants of platelet response to clopidogrel;Kubica;J Thromb Thrombolysis,2011

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

2. Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis;Frontiers in Cardiovascular Medicine;2024-02-19

3. Pharmacogenomics in clinical trials: an overview;Frontiers in Pharmacology;2023-10-20

4. Pharmacogenomics in Cardiovascular Diseases;Pharmacogenomics in Clinical Practice;2023

5. Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study;Frontiers in Pharmacology;2022-12-05